InvestorLens

CAPR — CAPRICOR THERAPEUTICS INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying CAPR?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
69
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their CAPR position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Paul Tudor Jones, Steve Cohen)
  • +4 tracked investors reported holding CAPR at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About CAPRICOR THERAPEUTICS INC (CAPR)

CAPRICOR THERAPEUTICS INC (CAPR) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $55M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in CAPR

100
/100
Strong Institutional Accumulation
Added / Increased6
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track CAPR

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

CAPR Ownership Composition

How CAPRICOR THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
69% of tracked value
Institutions
4
tracked investors
Total Reported
$79.8M
combined 13F value
Sectors2
  • Other68.7%
  • Hedge Funds31.3%
Other(3)
68.7%
Hedge Funds(1)
31.3%

Tracked investors reporting CAPR

  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    821.2K
    Value
    $25M
    % Portfolio
    0.03%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    1.4M
    Value
    $43.8M
    % Portfolio
    0.01%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    356.4K
    Value
    $10.8M
    % Portfolio
    0.00%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    7.2K
    Value
    $218.9K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold CAPR?
4 tracked institutional investors disclosed a position in CAPR (CAPRICOR THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of CAPR?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in CAPR, valued at $55M.
Did institutional ownership of CAPR increase or decrease?
Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 fully exited CAPR.
Where does this CAPR ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
CAPR (CAPRICOR THERAPEUTICS INC) — Institutional Holders & — InvestorLens